A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: A promising combination of two active drugs with a potential for synergism

Chemotherapy

Volumn 55, Issue 4, 2009, Pages 298-302

  Safra, T ^a   Bernstein Molho, R ^a   Menzcher, J ^b   Inbar, M ^a   Grisaru, D ^a,c   Levy, T ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c LIS MATERNITY HOSPITAL   (Israel)

Author keywords

Capecitabine; Docetaxel; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CAPECITABINE; DOCETAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EDEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; HAND FOOT SYNDROME; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TAXOIDS;

EID: 66749148880     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224658     Document Type: Article

References (29)

1. McGuire WP, Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340-348.
2. Hoskins WJ: Principles and Practice of Gynecologic Oncology. New York, Lippincott, 2005, pp 895-987.
3. McGuire WP, Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340-348.
4. Prefontaine M, Donovan JT, Powell JL, Buley L: Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Gynecol Oncol 1996;61:249-252.
5. Look KY, Blessing JA, Muss HB, DeGeest K: 5-Fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1992;15:494-496.
6. Look KY, Muss HB, Blessing JA, Morris M: A phase II trial of 5-fluorouracil and highdose leucovorin in recurrent epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 1995;18:19-22.
7. Long HJ, Nelimark RA, Su JQ, Garneau SC, Levitt R, Goldberg RM, et al: Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma. Gynecol Oncol 1994;54:180-183.
8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
9. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-1019.
10. Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, et al: Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002;20:2616-2623.
11. Vasey PA, McMahon L, Paul J, Reed N, Kaye SB: A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer 2003;89:1843-1848.
12. Makhnova EV, Gershanovich MI: Experience with Xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumor. Vopr Onkol 2003;49:193-197.
13. Boehmer CH, Jaeger W: Capecitabine in treatment of platinum-resistant recurrent ovarian cancer. Anticancer Res 2002;22:439-443.
14. Rischin D, Phillips K-A, Friedlander M, Harnett P, Quinn M, Richardson G, et al: A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol Oncol 2004;93:417-421.
15. Wolf JK, Bodurka DC, Verschraegen C, Sun CC, Branham D, Jenkins AD, et al: A phase II trial of oral capecitabine in patients with platinum-and taxane-refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 2006;102:468-474.
16. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-2308.
17. Pickart MJ, Gore M, ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, et al: Docetaxel a new active drug for the treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995;87:676-681.
18. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, et al: A phase II trial of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-842.
19. Maisano R, Mare M, Zavettieri M, Caristi N, Mesiti M, Scisca C, et al: Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 2003;23:1923-1926.
20. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
21. Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, et al: A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer 2003;98:1918-1924.
22. Lee JJ, Han JY, Kim HY, Kim HY, Chun JH, Lee HG, et al: A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer. Jpn J Clin Oncol 2006;36:761-767.
23. Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B, et al: Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung Cancer 2009;63:251-258.
24. Silva O, Lopes G, Morgenzstern D, Lobo C, Doliny P, Santos E, et al: A phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Clin Breast Cancer 2008;8:162-167.
25. Mrozek E, Ramaswamy B, Young D, Rhoades CA, Kendra K, Allen J, et al: Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clin Breast Cancer 2006;7:141-145.
26. Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell T, Nuovo G, et al: Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2005;11:1870-1876.
27. Garcia AA, Blessing JA, Lenz H-J, Darcy KM, Mannel RS, et al: Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:810-817.
28. Meyer F, Lueck A, Hribaschek A, Lippert H, Ridwelski K: Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma. Chemotherapy 2004;50:289-296.
29. Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, et al: Second-line combination chemotherapy with docetaxel for cisplatinpretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy 2007;53:449-453.